title: Use of depot medroxyprogesterone acetate and prevalent leiomyoma in young African American women.
abstract: OBJECTIVE
  Is use of depot medroxyprogesterone acetate (DMPA) a risk factor for or a protective factor against prevalent uterine leiomyoma?
  
  
  CONCLUSIONS
  Ever use of DMPA was associated with a decreased risk (adjusted risk ratio (RR): 0.8, 95% confidence interval (CI): 0.6, 0.9) of prevalent leiomyoma in young African American women.
  
  
  BACKGROUND
  Although progesterone is associated with growth of leiomyoma, previous epidemiological studies have shown a protective association for DMPA use. These previous studies may have been biased by studying clinically diagnosed leiomyoma (DMPA may mask symptoms thus delaying diagnoses).
  
  
  METHODS
  Cross sectional analysis of baseline data from a cohort study of 1696 African American women.
  
  
  METHODS
  Community-based recruitment (e.g. letters, flyers, radio and TV announcements) were used to enroll African American women between 23 and 34 years old without a previous diagnosis of leiomyoma in the Metropolitan Detroit area. Extensive questionnaire data were used to determine DMPA use and screening ultrasound detected the presence of leiomyoma ≥0.5 cm in diameter. Relative risks with adjustment for covariates were calculated for the presence of leiomyoma based on ever use of DMPA as well as duration and recency of use.
  
  
  RESULTS
  Among the 1696 volunteers who enrolled, 43% had used DMPA. Leiomyoma were detected in 17% of those who had ever used DMPA compared with 26% of those who had never used DMPA. The reduction in prevalence remained after adjustment for potential confounders and was highest among women who had used DMPA for more than 4 years (adjusted RR: 0.5, 95% CI: 0.3, 0.8). The reduction in risk was seen for women whose most recent use was up to 8 years prior to study enrollment.
  
  
  CONCLUSIONS
  The use of cross-sectional data means that the timing of initial fibroid development is not known, so the temporality of the association is uncertain. However in this sample of young women, most fibroids were small, suggesting that DMPA exposure may have occurred before leiomyoma development.
  
  
  CONCLUSIONS
  Our findings are in agreement with previous epidemiological studies, but protected from the bias inherent in the use of clinically diagnosed leiomyoma. Although further studies will be needed to elucidate the mechanism, use of DMPA as a contraceptive appears to provide long lasting protection against uterine leiomyoma.
  
  
  BACKGROUND
  No competing interests. This research was supported in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences, and in part by funds allocated for health research by the American Recovery and Reinvestment Act.
  
  
  BACKGROUND
  N/A.
authors.affiliation: Women's Health Group, Epidemiology Branch, National Institute of Environmental Health Sciences, PO Box 12233, MD A3-05, Research Triangle Park, NC 27709, USA quaker.harmon@nih.gov.
authors.forename: Q E
authors.initials: QE
authors.lastname: Harmon
authors.affiliation: Women's Health Group, Epidemiology Branch, National Institute of Environmental Health Sciences, PO Box 12233, MD A3-05, Research Triangle Park, NC 27709, USA.
authors.forename: D D
authors.initials: DD
authors.lastname: Baird
mesh_terms: D000328:Adult; D001741:Black or African American; D015331:Cohort Studies; D016001:Confidence Intervals; D003430:Cross-Sectional Studies; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000000981:diagnostic imaging / Q000517:prevention & control*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000627:therapeutic use*; D016017:Odds Ratio; D015995:Prevalence; D020011:Protective Agents / Q000627:therapeutic use*; D014463:Ultrasonography; D014591:Uterine Diseases / Q000000981:diagnostic imaging / Q000517:prevention & control*
chemical_list: D003692:Delayed-Action Preparations; D020011:Protective Agents; D017258:Medroxyprogesterone Acetate
keywords: African American women; contraception; leiomyoma; progesterone
references.citation: J Womens Health (Larchmt). 2014 Mar;23(3):224-30
references.pmid: 24443831
references.citation: Am J Obstet Gynecol. 1989 Mar;160(3):637-41
references.pmid: 2929683
references.citation: Endocr Rev. 2013 Feb;34(1):130-62
references.pmid: 23303565
references.citation: Mol Cell Endocrinol. 2012 Jul 25;358(2):223-31
references.pmid: 21672608
references.citation: N Engl J Med. 2012 Feb 2;366(5):409-20
references.pmid: 22296075
references.citation: Am J Obstet Gynecol. 2011 Jun;204(6):496.e1-6
references.pmid: 21492823
references.citation: Endocrinology. 2010 Jun;151(6):2433-42
references.pmid: 20375184
references.citation: Semin Reprod Med. 2010 May;28(3):204-17
references.pmid: 20414843
references.citation: Obstet Gynecol. 2008 Aug;112(2 Pt 1):387-400
references.pmid: 18669742
references.citation: Am J Obstet Gynecol. 2008 Apr;198(4):357-66
references.pmid: 18395031
references.citation: Br J Obstet Gynaecol. 1996 Sep;103(9):909-14
references.pmid: 8813312
references.citation: Br J Obstet Gynaecol. 1992 May;99(5):402-7
references.pmid: 1622913
references.citation: Fertil Steril. 2001 May;75(5):871-7
references.pmid: 11334896
references.citation: J Gynecol Obstet Biol Reprod (Paris). 2001 Apr;30(2):151-9
references.pmid: 11319467
references.citation: Hum Reprod Update. 2014 May-Jun;20(3):309-33
references.pmid: 24401287
references.citation: Am J Obstet Gynecol. 2003 Jan;188(1):100-7
references.pmid: 12548202
references.citation: Environ Health Perspect. 2003 Jun;111(8):1037-54
references.pmid: 12826476
references.citation: Am J Epidemiol. 2004 Jan 15;159(2):113-23
references.pmid: 14718211
references.citation: Int J Gynecol Pathol. 1985;4(2):89-96
references.pmid: 3926664
references.citation: J Womens Health (Larchmt). 2013 Oct;22(10):807-16
references.pmid: 24033092